<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928030</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-27871</org_study_id>
    <secondary_id>NCI-2013-01624</secondary_id>
    <secondary_id>BRS0032</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT01928030</nct_id>
  </id_info>
  <brief_title>Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer</brief_title>
  <official_title>Pilot Phase 1-2 Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1-2 trial studies the side effects and the best dose of recombinant human
      hyaluronidase and to see how well it works in treating lymphedema in patients with cancer.
      Recombinant human hyaluronidase (r-hu-hyaluronidase, rHuPH20) may reduce limb edema size in
      patients with lymphedema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, dose-escalation study followed by a phase 2 study.

      Phase 1: rHuPH20 subcutaneously (SC) on days 1, 3, 5, and 7

      Phase 2: rHuPH20 SC on days 1 to 21
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Adverse Events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Reported as any untoward medical occurrence or worsening of a pre-existing medical condition in a participant administered recombinant human hyaluronidase, and judged possibly, probably, or definitely related to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in Forearm Volume</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of patients that achieve a clinically significant reduction in lymphedema, assessed as a 20% reduction in excess forearm volume</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Lymphedema</condition>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>recombinant human hyaluronidase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant human hyaluronidase</intervention_name>
    <description>Given SC</description>
    <arm_group_label>recombinant human hyaluronidase</arm_group_label>
    <other_name>Chemophase</other_name>
    <other_name>rHuPH20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 2

          -  Unilateral upper limb secondary lymphedema

          -  Must have the ability to understand and the willingness to sign a written informed
             consent document

          -  Must agree to blood serum assessment including, complete blood count (CBC) with
             differential; comprehensive metabolic panel and serum osmolality at every sanctioned
             evaluation; additionally physician may require cardiac evaluation with echocardiogram,
             electrocardiogram, brain natriuretic peptide or urinalysis if deemed appropriate

          -  Must consent to multi-bio-frequency impedance analysis (MFBIA); the details are to be
             covered in consent

          -  Willing to sign consent for skin biopsies and phlebotomy

          -  Women of child bearing potential must have a documented negative pregnancy test within
             2 weeks prior to day 1 of treatment and agree to use a non-hormonal form of birth
             control during the duration of the trial therapy

        Exclusion Criteria:

          -  Pregnant or actively breast-feeding

          -  Bilateral upper extremity edema

          -  Bilateral manipulation of axilla within the last 24 months

          -  Active infections

          -  Receiving concomitant treatment for upper extremity lymphedema, or who have received
             treatment within the last 14 days

          -  Known allergic or hypersensitivity reaction to rHUPH20 or any hyaluronidase extracts

          -  Receiving concomitant diuretics or dihydropyridine class of calcium channel blockers;
             if an alternative medication is available, patient can become eligible after 3
             half-lives of drug discontinued and patient remains medically stable

          -  Grade 2 or greater hypo-albuminemia, serum sodium greater than 150meq/L, serum
             osmolality greater than 300mOsm/kg or blood urea nitrate/serum creatinine ratio
             greater than 25, within 7 days of screening

          -  Unable or unwilling to self/home administer subcutaneous experimental drug; study
             nurse or physician will train individuals on proper administration techniques

          -  Unwilling or incapable of maintaining a detailed log of number of injections, the
             date, time and site of administration

          -  Active malignancy; those undergoing active treatment for malignancy in the adjuvant
             setting are eligible; treatment can include chemotherapy, targeted therapy or
             anti-hormonal therapy

          -  At least 4 weeks removed from surgery or radiation in affected arm

          -  Primary lymphedema; if edema can be explained by systemic or congenital illnesses,
             that patient will not be eligible for this study

          -  Must not have any concurrent condition which in the investigator's opinion makes it
             inappropriate for the patient to participate in the trial or which would jeopardize
             compliance with the protocol

          -  Must not have received any investigational agents within 30 days prior to commencing
             study treatment

          -  Active thrombophlebitis

          -  Pulmonary edema, congestive heart failure or pulmonary embolus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Pegram</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanley Rockson</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <results_first_submitted>December 13, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2017</results_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mark Pegram</investigator_full_name>
    <investigator_title>Susy Yuan-Huey Hung Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>450 Units rHuPH20 (Days 1, 3, 5, and 7)</title>
          <description>Patients receive 450 units rHuPH20 SC on days 1, 3, 5, and 7</description>
        </group>
        <group group_id="P2">
          <title>900 Units rHuPH20 (Days 1, 3, 5, and 7)</title>
          <description>Patients receive 900 units rHuPH20 SC on days 1, 3, 5, and 7</description>
        </group>
        <group group_id="P3">
          <title>MTD rHuPH20 (Days 1 to 21)</title>
          <description>Days 1 to 21 Patients receive the maximum tolerated dose (MTD) of rHuPH20 SC on days 1 to 21.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hyaluronidase, Recombinant Human</title>
          <description>Patients receive recombinant human hyaluronidase 450 units or 900 units SC on days 1, 3, 5, and 7 (Phase 1) and then on days 1 to 21 (Phase 2) in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="56" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Adverse Events</title>
        <description>Reported as any untoward medical occurrence or worsening of a pre-existing medical condition in a participant administered recombinant human hyaluronidase, and judged possibly, probably, or definitely related to treatment</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>450 Units Recombinant Human Hyaluronidase (rHuPH20)</title>
            <description>Participants receive 450 units recombinant human hyaluronidase (rHuPH20) subcutaneously (SC) on Days 1, 3, 5, and 7 (Phase 1) and then on Days 1 to 21 (Phase 2) in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Adverse Events</title>
          <description>Reported as any untoward medical occurrence or worsening of a pre-existing medical condition in a participant administered recombinant human hyaluronidase, and judged possibly, probably, or definitely related to treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Forearm Volume</title>
        <description>Number of patients that achieve a clinically significant reduction in lymphedema, assessed as a 20% reduction in excess forearm volume</description>
        <time_frame>Up to 1 year</time_frame>
        <population>No participants received 900 units rHuPH20, and the MTD was not determined, so no participants received rHuPH20 at the MTD.</population>
        <group_list>
          <group group_id="O1">
            <title>450 Units rHuPH20 (Days 1, 3, 5, and 7)</title>
            <description>Patients receive 450 units rHuPH20 SC on days 1, 3, 5, and 7</description>
          </group>
          <group group_id="O2">
            <title>900 Units rHuPH20 (Days 1, 3, 5, and 7)</title>
            <description>Patients receive 900 units rHuPH20 SC on days 1, 3, 5, and 7</description>
          </group>
          <group group_id="O3">
            <title>MTD rHuPH20 (Days 1 to 21)</title>
            <description>Days 1 to 21 Patients receive the maximum tolerated dose (MTD) of rHuPH20 SC on days 1 to 21.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Forearm Volume</title>
          <description>Number of patients that achieve a clinically significant reduction in lymphedema, assessed as a 20% reduction in excess forearm volume</description>
          <population>No participants received 900 units rHuPH20, and the MTD was not determined, so no participants received rHuPH20 at the MTD.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Human Hyaluronidase</title>
          <description>Participants who received 450 units recombinant human hyaluronidase (rHuPH20) subcutaneously in Phase 1 were assessed in this outcome measure, treatment-related adverse events.
Biomarker analysis and pharmacology study were performed during study.
recombinant human hyaluronidase: Given subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema (injection site reaction)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Pegram, Susy Yuan-Huey Hung Professor</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-5801</phone>
      <email>mpegram@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

